RDA™ predicts breast cancer survival
Rna Diagnostics' RNA Disruption Assay™ (RDA™) can be highly useful in guiding chemotherapy treatment for women with breast cancer, based on research presented at the San Antonio Breast Cancer Symposium (SABCS
Dr. Amadeo Parissenti, Chief Scientific Officer at Rna Diagnostics and Professor, Laurentian University, presented with colleagues, “High tumor RNA disruption is
associated with increased survival in patients with locally advanced breast cancer”.
The findings, based on the NCIC MA.22 clinical trial of locally advanced breast cancer patients, showed that response to neo-adjuvant chemotherapy as determined by RDA™ early in treatment correlates highly with increased Disease Free Survival (DFS) at 5 years. Patients assessed by the RDA™ test during chemotherapy treatment as non-responders achieved considerably reduced DFS compared to patients assessed as responders. Non-responders had a mean DFS of 33 months survival versus 57 months for patients identified as responders. The RDA test stratifies chemotherapy breast cancer patients by disease free survival irrespective of tumour subtype.
Dr. Kenneth Pritzker, CEO of Rna Diagnostics, said “This study demonstrates that RDA™ can stratify patients by response to chemotherapy treatment early enough during treatment to guide modifications to the treatment delivered. By this very important criteria RDA appears superior to the standard prognostic biomarker, pathologic Complete Response (pCR).”
RnaDx Toronto team relocates
Rna Diagnostics' Toronto office has moved to the Banting Institute on College Street.
Left to right: Dr. Ken Pritzker, President & CEO, Laura Pritzker, Principal Scientist, Sanaa Noubir, Clinical Development Manager, Xiaohui Wang, Research Associate, John Connolly, VP Corporate Development, John Jordan, Chief Financial Officer